

December 22, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Conclusion of Syndicated Loan Agreement

TOKYO, Japan, December 22, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that SymBio concluded a syndicated loan (commitment line) agreement with MUFG Bank, Ltd. and the Bank of Yokohama, Ltd. (the "Agreement") as follows:

1. Purpose of the Agreement

The purpose of the agreement is to establish a stable and flexible financing system in line with business expansion.

2. Outline of the Syndicated Loan Agreement

Amount of Syndicated Loan	JPY 3,000 million
Execution Date	December 22, 2020
Form of Contract	Commitment line contract
Commitment Period	December 25, 2020 - June 24, 2022
Use of Funds	Working capital
Repayment Method	Lump-sum repayment on repayment date for each loan
Applicable Interest Rate	Base interest rate + spread
Collateral	Unsecured
Arranger and Agent	MUFG Bank, Ltd.
Participating Financial Institutions	MUFG Bank, Ltd. The Bank of Yokohama, Ltd.

3. Impact on Financial Outlook

SymBio does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2020.

Contact

Investor Relations

Tel: +81 (0)3 5472 1125